Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lori Coors

Ophthalmology Dallas, TX Medical Doctor

NPI 1427057223 CMS profile 19698

9600 N. Central Expressway, Suite 100, Dallas, TX 75231

Open in the dashboard

General payments

$6,346

104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$214,005 paid to institutions, not to them · program years 2023–2024

Through program year 2025, Lori Coors of Dallas, TX is reported in the CMS Open Payments database as having received $6,346 across 104 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $214,005 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $389 14
2024 General $451 14
2023 General $786 27
2022 General $590 20
2021 General $3,715 14
2020 General $14 1
2019 General $401 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lori Coors
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Lori Coors were reported at $389. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Lori Coors Ophthalmology median Middle half National median
2019 $401 $258 $104–$655 $163
2020 $14 $126 $45–$321 $114
2021 $3,715 $205 $76–$534 $132
2022 $590 $266 $100–$678 $149
2023 $786 $308 $117–$745 $160
2024 $451 $340 $127–$846 $164
2025 $389 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $3,700 7 payments
  2. Alimera Sciences, Inc. $398 6 payments
  3. Regeneron Healthcare Solutions, Inc. $375 15 payments
  4. Genentech USA, Inc. $337 10 payments
  5. AbbVie, Inc. $227 10 payments
  6. Horizon Therapeutics plc $227 13 payments
  7. Bausch & Lomb Americas Inc. $224 8 payments
  8. Coherus Biosciences Inc. $219 7 payments
  9. Astellas Pharma US Inc $186 7 payments
  10. Apellis Pharmaceuticals, Inc. $91 3 payments
  11. Other $361 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $3,430 1 payment
  2. Food and Beverage $2,871 101 payments
  3. Entertainment $30 1 payment
  4. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. Constellation Ophthalmology $3,477 3 payments
  2. VABYSMO $305 9 payments
  3. Cimerli $279 9 payments
  4. ILUVIEN $270 5 payments
  5. EYLEA HD $255 8 payments
  6. EYLEA $228 11 payments
  7. Constellation Ophthalmology $223 4 payments
  8. TEPEZZA $192 11 payments
  9. XIPERE $182 6 payments
  10. Izervay $146 5 payments
  11. Other $1,061 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

933

Median for Ophthalmology: 891

Drug cost

$21,047

Median for Ophthalmology: $68,233

Branded share of claims

6.8%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 303 $9,677
Brimonidine Tartrate Generic 52 $3,124
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 26 $2,284
Ofloxacin Generic 221 $2,079
Difluprednate Generic 13 $1,998
Latanoprost Generic 139 $1,169
Timolol Maleate Generic 28 $215
Erythromycin Erythromycin Base Brand 18 $209
Tramadol Hcl Generic 101 $125
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 19 $108

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$5,757,973

Of which drugs: $4,785,076

Medicare patients

1,959

Average age 78

Services billed

88,607

1,206 women, 753 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 32%
Diabetes 31%
Chronic kidney disease 24%
Atrial fibrillation 21%
Depression 19%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 437 3,683 $2,409,359
Injection, faricimab-svoa, 0.1 mg J2777 Office 225 70,080 $1,926,240
Injection, aflibercept hd, 1 mg J0177 Office 29 601 $157,829
Injection, avacincaptad pegol, 0.1 mg J2782 Office 14 1,820 $157,404
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg Q5128 Office 14 431 $80,061

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Cimerli
  • Sandoz Inc. $60
  • Coherus Biosciences Inc. $27
$87 — 431
OZURDEX
  • AbbVie, Inc. $79
$79 — —
Izervay
  • Astellas Pharma US Inc $65
$65 — 1,820
ILUVIEN
  • Alimera Sciences, Inc. $64
$64 — —
XIPERE
  • Bausch & Lomb Americas Inc. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record